Cargando…

The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation

Oral anticoagulants decreased stroke and mortality in atrial fibrillation patients. There have been cumulative data suggesting that some oral anticoagulants may exert favorable renal outcomes.The aim of this study is to evaluate the renal outcomes in patients with atrial fibrillation who took oral a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chantrarat, Thoranis, Hauythan, Sakolrat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342949/ https://www.ncbi.nlm.nih.gov/pubmed/34386573 http://dx.doi.org/10.1016/j.ijcha.2021.100844

Ejemplares similares

The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
por: Turpie, Alexander G.G., et al.
Publicado: (2017)

Tackling Nonatrial Fibrillation Diseases Using Nonvitamin K Antagonist Oral Anticoagulant: by What and for Whom?
por: Kim, Jong S.
Publicado: (2019)

Rate of anticoagulant use, and factors associated with not prescribing anticoagulant in older Thai adults with non-valvular atrial fibrillation: A multicenter registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2019)

Real‐world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease: A meta‐analysis
por: Dai, Qixin, et al.
Publicado: (2020)

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
por: Brown, Karen S., et al.
Publicado: (2016)

Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants
por: Morimoto, Yoshinari, et al.
Publicado: (2016)

Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
por: Sarah, Lessire, et al.
Publicado: (2014)

Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection
por: Mustanoja, Satu, et al.
Publicado: (2015)

Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study
por: Søgaard, Mette, et al.
Publicado: (2019)

Erratum to “Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants”
por: Lessire, Sarah, et al.
Publicado: (2014)

Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study
por: Han, Sola, et al.
Publicado: (2021)

Difference between the Upper and the Lower Gastrointestinal Bleeding in Patients Taking Nonvitamin K Oral Anticoagulants
por: Maruyama, Kyohei, et al.
Publicado: (2018)

Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
por: Gallù, Mariacarla, et al.
Publicado: (2020)

Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure: A case report
por: Shen, Long, et al.
Publicado: (2018)

Nonvitamin K oral anticoagulants with proton pump inhibitor cotherapy ameliorated the risk of upper gastrointestinal bleeding
por: Chaiyana, Parata, et al.
Publicado: (2023)

Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT‐AF II
por: Yao, Ren Jie Robert, et al.
Publicado: (2023)

Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment
por: Wilke, Thomas, et al.
Publicado: (2019)

Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2020)

Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS(2) score ⩾ 2
por: Fernandez, Maria M, et al.
Publicado: (2015)

The efficacy and safety outcomes of cardiac resynchronization therapy in patients with heart failure in Thailand: Phramongkutklao experience
por: Limprasert, Sarawuth, et al.
Publicado: (2021)

Changes in renal function and occurrence of contrast-induced nephropathy after percutaneous coronary interventions in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants or warfarin
por: Montone, Rocco A., et al.
Publicado: (2019)

A Comparison among Nonvitamin K Antagonist Oral Anticoagulants in Asian Patients with Venous Thromboembolism: A Multi-Institutional Study
por: Tsai, Ming-Lung, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
por: Wu, Olivia, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population‐based propensity‐weighted cohort study
por: Rodríguez‐Bernal, Clara L., et al.
Publicado: (2020)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Prevalence of oral anticoagulation in atrial fibrillation
por: Bartholomay, Eduardo, et al.
Publicado: (2014)

Medium-term and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation
por: Armentaro, Giuseppe, et al.
Publicado: (2023)

A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation
por: Zhou, Ling-Yun, et al.
Publicado: (2018)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Cardiovascular and renal protective effects of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation
por: Choi, Seong Huan, et al.
Publicado: (2022)

Comparison of Renal Function Estimation Formulae for Dosing Direct Oral Anticoagulants in Patients with Atrial Fibrillation
por: Lee, Kwang-No, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Safety and Efficacy of Direct Oral Anticoagulants for Atrial Fibrillation in Patients with Renal Impairment
por: Jang, Soo Min, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_13g32d0g4ihbr37sl7mfgv9bh2